SCHEMBL25408554

SCHEMBL25408554

Cc1cc(-c2cc(N)n(C)n2)no1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.41
▸ HTT P42858 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ RAB9A P51151 5/20 0.36
▸ NPC1 O15118 4/20 0.36
▸ MAPT P10636 1/20 0.34
▸ ADORA2B P29275 1/20 0.34
▸ HPGD P15428 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ APOBEC3G Q9HC16 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ TRPM8 Q7Z2W7 1/20 0.32
▸ NR1I2 O75469 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26847564 0.83 ALDH1A1 (0.38) POLBHTTALDH1A1KDM4ESMN1; SMN2
SCHEMBL25407489 0.77 RET (0.44) SMN1; SMN2RAB9ANPC1ADORA2B
SCHEMBL25407739 0.73 KDM4E (0.34) ALDH1A1KDM4EADORA2BCYP1A2
SCHEMBL26847565 0.68 RAB9A (0.37) POLBHTTALDH1A1KDM4EGAA
SCHEMBL12692670 0.67 HPGD (0.39) POLBHTTALDH1A1KDM4EGAA
SCHEMBL266468 0.66 — —
SCHEMBL25408598 0.66 CHRNA1 (0.36) SMN1; SMN2RAB9ANPC1ADORA2B
SCHEMBL2144710 0.66 ASIC3 (0.44) POLBHTTALDH1A1KDM4EGAA
SCHEMBL21597304 0.66 CA12 (0.35) SMN1; SMN2RAB9ANPC1MAPTADORA2B
SCHEMBL15813344 0.66 KMO (0.36) ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 — — EP disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 — — EP disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
CN-116615425-A Compounds and compositions as Sppl2a inhibitors 诺华股份有限公司 2023-08-18 — — CN disclosed
EP-4214210-A1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2023-07-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS SPPL2A, SPPL2B, BACE1 POLB 4457/4885HTT 3731/4885ALDH1A1 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback